What BMI for Mounjaro? NHS and private requirements explained

Simon Edward • 29 November 2025

Ready to start your weight loss journey? Download the free SemaPen app and find out if you're eligible in minutes.

Get Started Free

Want to know if you're eligible to take Mounjaro? Discover the threshold BMI for Mounjaro in private and NHS settings.



Want to know if you're eligible to take Mounjaro? Discover the threshold BMI for Mounjaro in private and NHS settings.

Before starting Mounjaro (tirzepatide), you'll need to know if you're eligible for a prescription. The eligibility requirements are partly based on your body mass index (BMI).


BMI is a basic calculation that estimates body fat based on weight and height. It's not a perfect indicator of health, but it's still the main tool used to decide who can access GLP-1 weight loss treatments in the UK.


Not every health provider has the same Mounjaro BMI requirements. Here's how NHS and private providers compare.


NHS vs private BMI for Mounjaro: a side-by-side look 

Mounjaro is available in the UK both on the NHS and through private providers (such as SemaPen). However, the BMI thresholds differ in each setting. 


We'll look at these differences in detail below. But first, here's a simple breakdown:


BMI Requirement Weight-related health condition is required Access pathway
NHS¹ At least 40 (or lower depending on ethnicity)* Yes, 4 out of 5 from a list of weight-related health problems** GP first, then referral to a specialist service
Private (e.g. SemaPen) At least 30 (or 27 to 29.9 depending on ethnicity or with related health issue) Yes (if BMI is 27 to 29.9) Private medical assessment

BMI for Mounjaro on the NHS: strict criteria and longer wait times

Mounjaro has been available through private providers in the UK since 2023. The NHS, meanwhile, started rolling it out to a small number of patients on 23 June 2025.


During this first phase of the rollout, you can only access Mounjaro if your GP refers you to a specialist weight management service.

To qualify, you generally need:


  • A BMI of 40 or above (or lower depending on ethnic background)*
  • Four out of five from a list of weight-related health conditions**

These rules have been designed so patients with the most urgent health needs can access Mounjaro first. The downside is that it can involve long waiting times, and only a limited number of people will meet the criteria.


To find out more, see the official NHS guidance.

* Research shows that Black, Asian and other minority ethnic groups with a BMI of 23+ are at a higher risk of developing type 2 diabetes and chronic illnesses. Hence, a lower BMI cutoff is recommended.


** Type 2 diabetes, high blood pressure, cardiovascular disease, obstructive sleep apnoea and high cholesterol.


Picture of a Mounjaro pen.

BMI for Mounjaro privately: faster access at a financial cost

Private providers generally allow more people to access Mounjaro.

They base their prescribing criteria on MHRA guidance, which allows people with a BMI of 30 or above to access Mounjaro. They also tend to take a more personalised and flexible approach to prescribing that's designed around your unique health profile.

You may be eligible to access Mounjaro privately if you meet the following criteria:

  • You have a BMI of 30 or above.
  • OR you have a BMI of 27 to 29.9, plus an obesity-related health issue like insulin resistance, prediabetes, high cholesterol or high blood pressure.
  • OR you're a person of a certain ethnic background and have a BMI of 27 to 29.9.*

At SemaPen, we ask our patients to fill out a secure online health assessment. One of our experts will then review the assessment to see if Mounjaro is safe and appropriate for you to use. Part of this process involves checking for any health conditions or medications you're taking that could affect your treatment.


This means you don't need a referral from your GP, so the process tends to be quicker and easier. (You must, however, inform your GP that you're taking the treatment.)

SemaPen: more than just BMI checks

Do you want to lose weight safely with Mounjaro and keep it off? If you meet our Mounjaro BMI requirements, our team of obesity experts is here to help you:



As well as prescription medication, our specialist medical weight lossplans come with smart scales that send weight updates to our team. That means we can watch your progress with you, and step in to provide tailored support to help you stay on track.


Are you ready to see what specialist medical weight loss support can do for you? Take the next step on your weight loss journey today by completing our online health assessment. Our obesity experts will review your answers and recommend the best treatment for you.


Sources


1. NHS England (n.d.) Weight management injections. Retrieved from: https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/


2. GOV.UK (2023) Press release: MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss. Retrieved from https://www.gov.uk/government/news/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss


This article was reviewed and approved by Lujain Alhassan, Bariatric Nutritionist, on 31 October 2025.


  • Average 15–21% weight loss
  • Trusted programmes built by UK experts
  • Personalised advice and support
  • Smart weight loss app to track progress and learn positive habits

Your journey starts in the app

Unlock tailored support, weight tracking and more.

1

Download the free app

2

Take your digital consultation

3

Start your programme

Download the app
Doctors look at several things when prescribing Wegovy. Find out what questions you'll be asked
by Simon Edward 2 March 2026
Doctors look at several things when prescribing Wegovy. Find out what questions you'll be asked – and why.
Metabolic syndrome is a cluster of conditions that can lead to complications like type 2 diabetes.
by Simon Edward 27 February 2026
Metabolic syndrome is a cluster of conditions that can lead to complications like type 2 diabetes. Could Mounjaro help treat it? Let's find out.
Have you noticed itchiness when taking Wegovy (semaglutide)? Learn what's normal
by Simon Edward 23 February 2026
Have you noticed itchiness when taking Wegovy (semaglutide)? Learn what's normal and when to be concerned.
There's a strong link between obesity and hypertension (high blood pressure). But what causes it?
by Simon Edward 20 February 2026
There's a strong link between obesity and hypertension (high blood pressure). But what causes it? And what can you do to lower your risk?
Mounjaro can be a big helping hand for weight loss – but that doesn't mean you can eat anything
by Simon Edward 16 February 2026
Mounjaro can be a big helping hand for weight loss – but that doesn't mean you can eat anything and still lose weight. Learn what dieticians recommend.
Several new weight loss treatments are in development, including Amgen's MariTide. Get the key facts
by Simon Edward 13 February 2026
Several new weight loss treatments are in development, including Amgen's MariTide. Get the key facts about this US-made injectable medication.
Are you considering using Wegovy for weight loss? Read our beginner's guide
by Simon Edward 9 February 2026
Are you considering using Wegovy for weight loss? Read our beginner's guide to get the key information you need in one place.
Did you know that extreme calorie-cutting can make losing weight more difficult? Learn why –
by Simon Edward 6 February 2026
Did you know that extreme calorie-cutting can make losing weight more difficult? Learn why – and what to do instead.
Clinical trials have shown that Mounjaro is safe and effective as a treatment for obesity
by Simon Edward 2 February 2026
Clinical trials have shown that Mounjaro is safe and effective as a treatment for obesity and type 2 diabetes. Let's explore their findings in more detail.
Discover more about the FLOW study semaglutide trial, which looked at how Wegovy could lower risks
by Simon Edward 31 January 2026
Discover more about the FLOW study semaglutide trial, which looked at how Wegovy could lower risks in people with chronic kidney disease.
More posts